US biotech Ziopharm Oncology (Nasdaq: ZIOP) closed more than 18% down on Monday after its Phase I trial of CD19-specific CAR-T therapies hit a roadblock before it had started.
Ziopharm differentiates its approach by saying that it could develop a decentralized, rapid manufacturing process based in hospitals that avoids the processing expenses of currently-marketed CAR-T therapies.
"We know what is needed to address the hold issues"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze